Full Text Journal Articles by
Author Abhishek D Garg

Advertisement

Find full text journal articles






Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages.

Aleksandar Murgaski, Máté Kiss, Helena Van Damme, Daliya Kancheva, Isaure Vanmeerbeek, Jiri Keirsse, Eva Hadadi, Jan Brughmans, Sana M Arnouk, Ahmed E I Hamouda, Ayla Debraekeleer, Victor Bosteels, Yvon Elkrim, Louis Boon, Sabine Hoves, Niels Vandamme, Sofie Deschoemaeker, Sophie Janssens, Abhishek D Garg, Greetje Vande Velde, Martina Schmittnaegel, Carola H Ries, Damya Laoui,

Agonistic αCD40 therapy has been shown to inhibit cancer progression in only a fraction of patients. Understanding the cancer cell-intrinsic and microenvironmental determinants of αCD40 therapy response is therefore crucial to identify responsive patient populations and design efficient combinatorial treatments. Here, we show that the therapeutic efficacy of αCD40 in ... Read more >>

Cancer Res (Cancer research)
[2022, :CAN-22-0094]

Cited: 0 times

View full text PDF listing >>



Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines.

Michal Hensler, Jana Rakova, Lenka Kasikova, Tereza Lanickova, Josef Pasulka, Peter Holicek, Marek Hraska, Tereza Hrnciarova, Pavla Kadlecova, Andreu Schoenenberger, Klara Sochorova, Daniela Rozkova, Ludek Sojka, Jana Drozenova, Jan Laco, Rudolf Horvath, Michal Podrazil, Guo Hongyan, Tomas Brtnicky, Michal J Halaska, Lukas Rob, Ales Ryska, An Coosemans, Ignace Vergote, Abhishek D Garg, David Cibula, Jirina Bartunkova, Radek Spisek, Jitka Fucikova,

Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical efficacy of DC-based vaccines remains suboptimal, largely reflecting local and systemic immunosuppression at baseline. An autologous DC-based vaccine (DCVAC) has recently been shown to improve progression-free survival and overall survival ... Read more >>

Oncoimmunology (Oncoimmunology)
[2022, 11(1):2101596]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

0.5716 s